Genentech Aims For Broad Access To Avastin In Cervical Cancer, But Needs To Figure Out How To Get There
Executive Summary
FDA approval is fifth indication for Roche/Genentech’s Avastin. Number of cases in the U.S. is low and set to decline with better prevention, but disease is considered a major global health problem.
You may also be interested in...
Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
Avastin Takes One Step Forward, One Step Back At ASCO
Genentech’s bevacizumab was the subject of one study supporting use in cervical cancer and one failing to show an effect in first-line brain cancer. A separate study repeated the disappointing brain cancer results, but the sponsor sees a silver lining in the quality of life dataset.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.